Skip to main content

PRESS RELEASES

Date Title  
Toggle Summary Seres Therapeutics Issues Statement Regarding U.S. Food and Drug Administration Safety Alert Related to Use of Fecal Microbiota Transplantation
FDA alert does not impact Seres’ microbiome investigational therapeutic candidates CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 19, 2019-- Seres Therapeutics, Inc . (Nasdaq: MCRB) (“Seres”) today provided a statement on a safety alert from the U.S. Food and Drug Administration ( FDA ) regarding
Toggle Summary Seres Therapeutics, Inc. Announces Pricing of Public Offering of Common Stock
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 13, 2019-- Seres Therapeutics, Inc. (Nasdaq: MCRB) (“Seres”), a leading microbiome therapeutics platform company developing a novel class of biological drugs that are designed to treat disease by restoring the function of a dysbiotic microbiome, today
Toggle Summary Seres Therapeutics, Inc. Announces Proposed Public Offering of Common Stock
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 12, 2019-- Seres Therapeutics, Inc. (Nasdaq: MCRB) (“Seres”), a leading microbiome therapeutics platform company developing a novel class of biological drugs that are designed to treat disease by restoring the function of a dysbiotic microbiome, today
Toggle Summary Seres Therapeutics to Present at the Jefferies 2019 Healthcare Conference
CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 29, 2019-- Seres Therapeutics, Inc . (Nasdaq: MCRB) today announced that it will present at the Jefferies 2019 Healthcare Conference in New York, NY on Wednesday, June 5 th at 2:30 p.m. ET . A live audio webcast of the presentation will be available under the
Toggle Summary Seres Therapeutics Reports First Quarter Financial Results and Provides Clinical Pipeline Progress Update
- Four significant microbiome program milestones expected during 2020, including readouts from two late-stage development programs – - SER-287 Fast Track designation obtained for active mild-to-moderate ulcerative colitis; Phase 2b study enrollment expected to be completed by mid-2020 and top-line
Toggle Summary Seres Therapeutics to Host First Quarter 2019 Financial Results and Operational Progress Conference Call and Webcast on May 2, 2019
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Apr. 29, 2019-- Seres Therapeutics, Inc . (NASDAQ:MCRB) today announced that management will host a conference call and live audio webcast on May 2, 2019 at 8:30 a.m. ET to discuss first quarter 2019 results and provide a general business update.
Toggle Summary Seres Therapeutics Presents New Preclinical Data Supporting the Development of SER-401 for Immuno-Oncology at the 2019 American Association for Cancer Research Annual Meeting
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Apr. 2, 2019-- Seres Therapeutics, Inc . (Nasdaq: MCRB) today announced that new preclinical data supporting the development of microbiome therapeutics for immuno-oncology (poster title “Leveraging gut microbiota networks to impact tumor immunotherapy”) 1 will be
Toggle Summary Seres Therapeutics Announces Microbiome Immuno-Oncology Focused Collaboration with AstraZeneca
- Collaboration focused on further elucidating the potential of microbiome therapeutics to augment immuno-oncology treatment for cancer – - Seres to receive $20 million and financial support for research activities – - Company to further discuss collaboration during webcast Cowen healthcare
Toggle Summary Seres Therapeutics Reports Fourth Quarter and Full Year Financial Results and Provides Operational Updates
- Initiated SER-287 Phase 2b study in mild-to-moderate ulcerative colitis - - Initiated SER-401 Phase 1b study in metastatic melanoma - - Conference call at 8:30 a.m. ET today - CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar. 6, 2019-- Seres Therapeutics, Inc.
Toggle Summary Seres Therapeutics to Present at Three Upcoming March Conferences
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar. 5, 2019-- Seres Therapeutics, Inc . (Nasdaq: MCRB) today announced that it will present at each of the following upcoming healthcare conferences: Chardan’s Inaugural Microbiome Summit : a corporate overview will be presented on Thursday, March 7 th at 8:10

Back to top